Analysis of relapses in anti-NMDAR encephalitis

IDIBAPS August Pi i Sunyer Biomedical Research Institute, Barcino, Catalonia, Spain
Neurology (Impact Factor: 8.29). 08/2011; 77(10):996-9. DOI: 10.1212/WNL.0b013e31822cfc6b
Source: PubMed


The clinical characteristics of patients with relapsing anti-NMDA receptor (NMDAR) encephalitis are not well-defined. In this study, we report the clinical profile and outcome of relapses in a series of anti-NMDAR encephalitis.
We did a retrospective review of relapses that occurred in 25 patients with anti-NMDAR encephalitis. Relapses were defined as any new psychiatric or neurologic syndrome, not explained by other causes, which improved after immunotherapy or, less frequently, spontaneously.
A total of 13 relapses were identified in 6 patients. Four of them had several, 2 to 4, relapses. There was a median delay of 2 years (range 0.5 to 13 years) for the first relapse. Median relapse rate was 0.52 relapses/patient-year. Relapse risk was higher in patients who did not receive immunotherapy in the first episode (p = 0.009). Most cases (53%) presented partial syndromes of the typical anti-NMDAR encephalitis. Main symptoms of relapses were speech dysfunction (61%), psychiatric (54%), consciousness-attention disturbance (38%), and seizures (31%). Three relapses (23%) presented with isolated atypical symptoms suggestive of brainstem-cerebellar involvement. An ovarian teratoma was detected at relapse in only 1 patient (17%). Relapses did not add residual deficit to that caused by the first episode.
Relapses in anti-NMDAR encephalitis are common (24%). They may occur many years after the initial episode. Relapses may present with partial aspects or with isolated symptoms of the full-blown syndrome. Immunotherapy at first episode reduces the risk of relapses.

Download full-text


Available from: Iñigo Gabilondo, Nov 14, 2014
  • Source
    • "Following this dramatic picture, one to three relapses can occur in patients who improve [2]. The risk for a relaps increases in patients who receive no immunotherapy following the first attack, and who have no tumor [3]. Neuromyelitis optica is an inflammatory, demyelinating disease caused by autoantibodies against a protein so called aquaporin [4] (AQP4) located in the water channels of astrocytes, involving optic nerves and the spinal cord. "
    [Show description] [Hide description]
    DESCRIPTION: Relaps of NMDA Encephalitis Superimposed Upon Neuromiyelitis Optica.
    Full-text · Research · Sep 2015
  • Source
    • "And in their review of literature, in 109 anti-NMDAR-encephalitis patients elevated cell counts were found in 79/107 (74%) patients and elevated protein counts in 30/101 (30%) patients. while some case series reported slight CSF changes [1] [15] [16]. These studies are consistent in showing that in patients with anti-NMDAR-encephalitis, CSF findings are either normal or exhibit only slight changes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-NMDAR-encephalitis is a recently described form of autoimmune encephalitis. Here, we characterize CSF changes in Chinese patients with anti-NMDAR encephalitis, and explore the relationship between CSF findings and disease outcome. The presence of NMDAR antibodies in serum or CSF samples was evaluated in patients diagnosed with encephalitis between October 1, 2010 and August 1, 2014 at the West China Hospital. All patients fulfilling our diagnostic criteria were included and CSF findings were analyzed. Patient outcome was assessed after 4, 8, 12, 16, 20, and 24 months using the modified Rankin scale (mRS). Out of 3000 people with encephalitis screened, 43 patients were anti-NMDAR antibody positive in CSF or serum and included in this study. 62.8% of the patients identified with positive CSFs had positive serum anti-NMDAR samples, while 100% patients with positive serum had positive CSF samples. In the CSF white cell counts were elevated in 58.1% of cases; protein was increased in 18.6%; QAlb>Qlim(Alb) of the blood-CSF barrier was found in 29.3%; intrathecal immunoglobulin synthesis was detected in 17.1%, and 39.5% patients exhibited increased CSF pressures. A longer follow-up period was associated with better outcomes. There was no relationship between changes in CSF findings and outcome. The sensitivity of NMDA receptor antibody testing is higher in CSF compared to serum. Other CSF abnormalities are present in some patients with Anti-NMDAR-encephalitis, however these changes do not appear to affect prognosis. Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
    Full-text · Article · Apr 2015 · Seizure
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’encéphalite aiguë reste une cause fréquente d’admission en réanimation pédiatrique. Bien que la majorité soit d’origine infectieuse, les encéphalites non infectieuses restent mal connues, leur diagnostic et leur traitement souvent retardés. Nous présentons ici les principales causes d’encéphalites aiguës non infectieuses comme l’encéphalomyélite aiguë disséminée, l’encéphalite liée au syndrome d’activation macrophagique, l’encéphalopathie d’Hashimoto, les encéphalites antirécepteurs de l’acide N-méthyl-D-aspartique (NMDA) et les fever-infection related epilepsy syndrome (FIRES)/devastating epilepsy in school-age children (DESC) syndrome.
    No preview · Article · Jan 2012 · Réanimation
Show more